Skip to content

EVOKE PHARMA, INC.: 10-Q filed 2014-08-13

What EVOKE PHARMA, INC. reported in its quarterly report filed 2014-08-13 (fiscal Q2 2014): 17 published measures, 50 facts as tagged in accession 0001193125-14-308400.

This filing

Form
10-Q (quarterly report)
Filed
2014-08-13
Fiscal period
fiscal Q2 2014
Accession
0001193125-14-308400 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All EVOKE PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-06-3017,023,161USD
At 2013-12-3124,986,458USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-06-301,853,904USD
At 2013-12-313,803,197USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-06-3015,169,257USD
At 2013-12-3121,183,261USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-06-3016,045,799USD
At 2013-12-3124,196,691USD
At 2013-06-301,050,439USD
At 2012-12-31116,013USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-04-01 to 2014-06-30-3,547,040USD91
2014-01-01 to 2014-06-30-6,502,524USD181
2013-04-01 to 2013-06-30-239,871USD91
2013-01-01 to 2013-06-30-733,863USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-06-30-29,193,992USD
At 2013-12-31-22,691,468USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-04-01 to 2014-06-30265,210USD91
2014-01-01 to 2014-06-30488,520USD181
2013-04-01 to 2013-06-303,126USD91
2013-01-01 to 2013-06-306,252USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-04-01 to 2014-06-30-3,491,865USD91
2014-01-01 to 2014-06-30-6,414,460USD181
2013-04-01 to 2013-06-30-203,424USD91
2013-01-01 to 2013-06-30-535,454USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-06-3016,934,702USD
At 2013-12-3124,430,953USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-06-301,837,015USD
At 2013-12-312,284,906USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2014-04-01 to 2014-06-303,491,865USD91
2014-01-01 to 2014-06-306,414,460USD181
2013-04-01 to 2013-06-30203,424USD91
2013-01-01 to 2013-06-30535,454USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-04-01 to 2014-06-302,874,977USD91
2014-01-01 to 2014-06-304,727,093USD181
2013-04-01 to 2013-06-30130,846USD91
2013-01-01 to 2013-06-30241,827USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-06-306,099,547shares
At 2013-12-316,096,752shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-06-3044,362,639USD
At 2013-12-3143,874,119USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2014-06-3088,459USD
At 2013-12-31555,505USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-04-01 to 2014-06-30616,888USD91
2014-01-01 to 2014-06-301,687,367USD181
2013-04-01 to 2013-06-3072,578USD91
2013-01-01 to 2013-06-30293,627USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2014-04-01 to 2014-06-30-55,175USD91
2014-01-01 to 2014-06-30-88,064USD181
2013-04-01 to 2013-06-30-36,447USD91
2013-01-01 to 2013-06-30-198,409USD181

Inspect the source

Entity
EVOKE PHARMA, INC. / CIK 0001403708
Captured
2026-09-21T17:19:23.305Z
SEC response SHA-256
1d2ea0edbbb48066d62d49983dacdd25cf55cdf81e3ee5a742e26303a1f7d06e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001403708.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))